Posted by Michael Wonder on 23 Oct 2024
Health Canada approves first and only oral targeted treatment for brain cancer
22 October 2024 - Pivotal Phase 3 study shows significant improvement in progression-free survival with a favourable safety profile.
Servier Canada is pleased to announce the approval and commercial availability of Voranigo (vorasidenib tablets), the first targeted therapy for the treatment of grade 2 isocitrate dehydrogenase mutant glioma in adults and paediatric patients aged 12 years and older, following surgery.
